Atopic Dermatitis

Adults with a clinical diagnosis of atopic dermatitis (AD) are needed for this clinical research trial. Eligible participants must have experienced symptoms for at least 3 years. Participants also must either have a history of inadequate response to previous systemic treatments for AD, or that other systemic treatments have been medically inadvisable. All participants will receive investigational oral or subcutaneous injection (SC) treatments (active study drugs) during the treatment period. You will not be charged for study medication and study-related assessments.

Reimbursement for study-related expenses (such as travel expense) will be provided. Study participation will last between 25-41 weeks and involve about 10 visits to the study centre.

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis – Full Text View – ClinicalTrials.gov